Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.95 USD
Change Today 0.00 / 0.00%
Volume 0.0
GEDSF On Other Exchanges
As of 4:30 PM 02/25/15 All times are local (Market data is delayed by at least 15 minutes).

richter gedeon -spons gdr (GEDSF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/27/14 - $16.00
52 Week Low
02/25/15 - $14.95
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

richter gedeon -spons gdr (GEDSF) Related Businessweek News

No Related Businessweek News Found

richter gedeon -spons gdr (GEDSF) Details

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. engages in the research, development, manufacture, sale, and marketing of pharmaceutical products in Hungary, the European Union, the Commonwealth of Independent States, the United States, China, Latin America, and internationally. It operates through Pharmaceuticals, and Wholesale and Retail segments. The company develops products for various therapeutic areas, including gynaecology, cardiovascular, gastrointestinal, central nervous system, muscle relaxants, and others. Its gynecological products include contraceptives, emergency contraceptives, hormone replacements, fungicides, and preparations used for the treatment of uterine fibroids; and contraceptive devices, as well as products for menopausal care, pregnancy care and obstetrics, gynaecological infections, and other gynaecological conditions; and central nervous system products comprise products for the treatment of chronic cerebral circulatory disorders, anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as a product for the treatment of neuropathic pain. The company also offers products for the prevention and treatment of various cardiovascular diseases. In addition, it produces various over-the-counter pharmaceutical products for various health problems, including Escapelle (Postinor), an emergency contraceptive pill; Panangin for supporting cardiovascular health; Stopdiar to treat diarrhea; Lordestin and Zilola for allergy; and Curiosin for wound care. Further, the company operates 108 pharmacy units. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.

11,602 Employees
Last Reported Date: 04/2/15
Founded in 1901

richter gedeon -spons gdr (GEDSF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

richter gedeon -spons gdr (GEDSF) Key Developments

Gedeon Richter Approves Dividend

Shareholders of Gedeon Richter approved payment of a HUF 33 per share dividend on 2014 earnings at an annual general meeting on April 28, 2015. The HUF 6.15 billion dividend will be paid from the company’s after-tax profit of HUF 19.11 billion, calculated according to Hungarian Accounting Standards. The remaining HUF 12.96 billion will be placed into profit reserves the board's dividend proposal was in line with the company's practice of returning one-fourth of IFRS after-tax profit to shareholders. Last year, the company shareholders approved a HUF 57 per share dividend on 2013 earnings.

Gedeon Richter Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Gedeon Richter reported consolidated earnings results for the year ended December 31, 2014. For the period, the company reported total revenue of HUF 353,709 million against HUF 351,886 million a year ago. Profit from operations was HUF 37,747 million against HUF 46,446 million a year ago. Profit before income tax was HUF 25,795 million against HUF 43,636 million a year ago. Profit attributable to Owners of the parent was HUF 24,950 million or HUF 134 per diluted share against HUF 42,766 million or HUF 229 per diluted share a year ago. Net cash flow to operating activities was HUF 62,201 million against HUF 73,942 million a year ago. Payments for property, plant and equipment was HUF 28,406 million against HUF 25,302 million a year ago. Payments for intangible assets was HUF 14,828 million against HUF 8,304 million a year ago. Net debt was HUF 39,260 million against HUF 46,759 million a year ago. EBITDA was HUF 67,435 million against HUF 75,720 million a year ago.

Gedeon Richter Proposes Dividend

Gedeon Richter announced that its board would propose to shareholders payment of a HUF 33 per share dividend on 2014 earnings at an annual general meeting on April 28, 2015. The dividend fund will reach about HUF 6.2 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEDSF:US $14.95 USD 0.00

GEDSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.126.10 CHF +2.10
Dr Reddy's Laboratories Ltd 3,388 INR -7.00
Endo International PLC $86.31 USD +1.26
Pharmstandard OJSC 980.00 RUB 0.00
Medicines Co/The $26.39 USD -0.68
View Industry Companies

Industry Analysis


Industry Average

Valuation GEDSF Industry Range
Price/Earnings 32.9x
Price/Sales 2.3x
Price/Book 1.5x
Price/Cash Flow 32.9x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RICHTER GEDEON -SPONS GDR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at